Post essential thrombocythemia myelofibrosis (et-MF)

Clinical trials for Post essential thrombocythemia myelofibrosis (et-MF) explained in plain language.

Never miss a new study

Get alerted when new Post essential thrombocythemia myelofibrosis (et-MF) trials appear

Sign up with your email to follow new studies for Post essential thrombocythemia myelofibrosis (et-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New drug reparixin aims to control myelofibrosis when standard treatment fails

Disease control Recruiting now

This phase 2 study tests the drug reparixin in 10 people with myelofibrosis, a type of bone marrow cancer. Participants have advanced disease and cannot take or have not responded to standard JAK inhibitor therapy. They take reparixin pills three times daily for 6 months, with th…

Matched conditions: POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (ET-MF)

Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control

Last updated Jun 27, 2026 12:29 UTC

Post essential thrombocythemia myelofibrosis (et-MF)

Get alerted when new Post essential thrombocythemia myelofibrosis (et-MF) trials appear

New drug reparixin aims to control myelofibrosis when standard treatment fails